BACHEM HOLDING history

Expansion into non-European markets began with the founding of Bachem Bioscience, Inc. in Philadelphia, USA, in 1987.

In 1995, the facilities, including the quality control department, were expanded to a total of 168,000 sq. ft. (15,600 m2). The number of employees grew to 190.

In 1996, it acquired the second largest manufacturer of peptides, Bachem California in Torrance, USA, together with its subsidiaries in Germany and the UK.

The acquisition of Sochinaz SA, a Swiss-based (Vionnaz) specialized manufacturer of active pharmaceutical ingredients in 2001, strengthened Bachem’s expertise and once again expanded its manufacturing capabilities.

In 2003, a holding structure was introduced to align the factual organization of the company with an appropriate legal structure and to support management structure adjustments, given by continued company growth requirements.

In 2007, Bachem aquired the Clinalfa® brand Merck Biosciences for Bachem’s ready-to-use clinical trial materials and related services.

In 2013, GlyTech, Inc. (Kyoto, Japan) and Bachem informed that they have successfully co-developed a chemical synthesis of Interferon β-1a applicable for industrial scale.

In 2015, Bachem acquires the American Peptide Company (APC), also specialized in the production of peptides and based in Vista, California, thereby increasing its expertise and production volume.

In 2016, the Group’s most modern building for R&D projects and small series production was put into operation in Bubendorf.

As of 2018, Bachem will also have a physical presence in Asia with a further regional foothold in addition to Europe and North America.

In 2019, work on expanding the oligonucleotide portfolio is proceeding at full speed.

The year 2020 is characterized by a high investment volume at all sites.